
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is well-positioned to make a significant impact in the treatment of schizophrenia with its innovative drug candidate, roluperidone. The drug's strong efficacy and safety profile, along with its unique mechanism of action and potential for monotherapy use, make it a promising option for patients and investors alike. With a large market and ongoing clinical trials, the company has the potential for strong financial growth and success.
Bears say
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary product candidates for treating CNS diseases. Despite past trials demonstrating efficacy in schizophrenia patients with negative symptoms and mitigating potential adverse effects, their global Phase 3 trial did not meet statistical significance due to an elevated placebo effect, increasing risk and peak penetration potential. With the average age of onset of schizophrenia at ~26 years old and a large global market, Minerva has a significant opportunity for growth, but the company's current valuation is not justified.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares